Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Rhea-AI Summary
Erasca (Nasdaq: ERAS) exercised its option to expand the ERAS-0015 license with Joyo to include China, Hong Kong, and Macau, securing worldwide rights for the pan-RAS molecular glue. Erasca will make a one-time payment tied to Joyo’s development stage and plans unified global development.
ERAS-0015 has shown promising early clinical activity across multiple tumor types and RAS mutations at low doses; initial Phase 1 monotherapy data are expected in H1 2026.
Positive
- Worldwide rights secured for ERAS-0015 including China, Hong Kong, Macau
- Unified global development strategy enabled by expanded license
- Initial Phase 1 monotherapy data expected in H1 2026
- Early clinical activity reported across multiple tumor types and RAS mutations
Negative
- One-time payment obligation to Joyo based on development stage
- Clinical data are early and pending formal Phase 1 readout in H1 2026
News Market Reaction – ERAS
On the day this news was published, ERAS declined 1.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ERAS was up 1.87% pre-news while peers showed mixed moves: OLMA +18.17%, PRTA +5.83%, ZVRA +3.52%, ITOS +0.10%, ALMS -0.22%. Momentum scanner flagged ZVRA (+15.35%) and PRTA (+2.04%) up, REPL down (-1.62%). With peers moving in varying directions and no same-day peer news, ERAS’s setup looks more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Clinical collaboration | Positive | +2.8% | Collaboration with Tango to test ERAS-0015 plus vopimetostat in MTAP-deleted tumors. |
| Feb 24 | Patent issuance | Positive | +4.5% | U.S. patent granted for pan-KRAS inhibitor ERAS-4001, extending IP protection. |
| Feb 05 | Investor conferences | Neutral | +5.7% | Management participation in two healthcare conferences with webcasted presentations. |
| Jan 23 | Equity offering close | Negative | -3.5% | Closing of upsized common stock offering at $10.00 with $258.8M gross proceeds. |
| Jan 21 | Equity offering pricing | Negative | +2.4% | Pricing of upsized $10.00 per share equity offering with underwriters’ option. |
Across recent news, ERAS has mostly moved in the same direction as the apparent tone of announcements, including both positive R&D updates and financing actions, with only one notable divergence on offering pricing.
Over the last few months, Erasca has reported several notable milestones. A March 5, 2026 collaboration with Tango around ERAS-0015 and a February 24, 2026 U.S. patent for ERAS-4001 both saw positive price reactions. Earlier, conference participation in February 2026 also coincided with gains. Two January 2026 equity offerings, announced and then closed at $10.00 per share, showed mixed but mostly aligned reactions with their dilutive nature. Today’s expansion to worldwide rights for ERAS-0015 builds on this sequence of RAS-focused pipeline and capital-raising developments.
Regulatory & Risk Context
An S-3 shelf filed on 2025-08-12 allows Erasca to offer up to $500,000,000 in securities, including up to $200,000,000 of common stock via an at-the-market program with Jefferies LLC. The shelf is noted as not currently effective and has seen 2 usage events via 424B5 supplements in January 2026.
Market Pulse Summary
This announcement expands Erasca’s license to secure worldwide rights for ERAS-0015, supporting a unified global development and commercialization plan. It builds on recent collaboration and patent updates around the company’s RAS-focused pipeline and points toward initial Phase 1 monotherapy data in H1 2026. Investors may watch how global trial execution, future financing under the existing shelf, and any further insider activity interact with clinical readouts for ERAS-0015.
Key Terms
pan-ras molecular glue medical
phase 1 medical
monotherapy medical
ras/mapk pathway medical
AI-generated analysis. Not financial advice.
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy
ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent
Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will provide Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015.
Under the terms of the ERAS-0015 license agreement, Erasca exercised its option to convert its territory to worldwide and is obligated to make a one-time payment to Joyo based on the stage of Joyo’s development program. Securing rights in China, Hong Kong, and Macau will provide Erasca with exclusive global rights for ERAS-0015, enabling the company to pursue a unified worldwide development and commercialization strategy.
“We are encouraged by the early clinical activity observed for ERAS-0015 across multiple tumor types and RAS mutations at a fraction of the dose seen for RMC-6236. We believe that the clinical data generated to date, including what we have observed from a substantial number of patients treated in China, underscore the potential differentiation and benefit of ERAS-0015 for patients with RAS-mutant cancers globally,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Exercising this option to expand our license agreement and secure worldwide rights reflects our strong conviction in ERAS-0015’s potential, and we look forward to collaborating with the Chinese investigators to continue developing ERAS-0015 for patients in China and globally.”
Erasca is advancing ERAS-0015 in the ongoing AURORAS-1 Phase 1 dose escalation trial in patients with RAS-mutant solid tumors with initial Phase 1 monotherapy data expected in the first half of 2026.
About ERAS-0015
ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability, well-behaved, linear PK, and confirmed and unconfirmed responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed and unconfirmed partial responses at doses as low as 8 mg once daily (QD). In preclinical studies versus RMC-6236, ERAS-0015 demonstrated approximately 8-21 times higher binding affinity to cyclophilin A (CypA), approximately 5 times greater potency in RAS inhibition, and greater in vivo antitumor activity evidenced by achieving comparable or greater tumor growth inhibition or regression at doses that are as low as approximately one-tenth to one-fifth of the dose of RMC-6236. ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-0015, and the planned advancement of our development pipeline, including the anticipated timing of the planned data readout for the AURORAS-1 trial, our belief that the clinical data generated to date further underscore the differentiated potential of ERAS-0015 for patients with RAS-mutant cancers, our strong conviction in ERAS-0015 and its potential benefit for patients, the timing and amount payable in connection with exercising the option to expand our rights under the Joyo license agreement, our ability to collaborate with Chinese investigators to continue developing ERAS-0015 for patients in China, and our ability to continue the development of ERAS-0015 globally. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; observations regarding the first dosage level at which a clinical response is detected are based on data generated within individual clinical trials, and comparisons of such clinical observations across different trials involve data from separate trials with distinct designs, patient populations, and methodologies, and therefore may not be directly comparable; risks related to disagreements between the parties as to the amount of the option exercise payment based on the stage of the development program; any forward-looking statements regarding dose-response relationships reflect current expectations and/or assumptions are subject to risks and uncertainties that could cause actual results to differ materially; our observations of clinical data in China is based on data generated by the licensor; our assumptions about the development potential of ERAS-0015 are based in large part on the preclinical data generated by the licensor and we may observe materially and adversely different results as we conduct our planned studies and trials; our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical studies not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; the sufficiency of our cash, cash equivalents, and marketable securities to fund operations; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
FAQ
What rights did Erasca (ERAS) secure for ERAS-0015 on March 10, 2026?
When will Erasca (ERAS) report initial Phase 1 monotherapy data for ERAS-0015?
How did Erasca describe ERAS-0015’s early clinical activity compared with other RAS agents?
Does the ERAS-0015 license expansion require any payment from Erasca (ERAS)?
What strategic benefit does worldwide rights to ERAS-0015 provide Erasca (ERAS)?
